Additional file 6 of An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities

Supplementary Material 6. Supplementary Fig. 6.pdf – Assessment of toxicity with IgE administration immunocompetent syngeneic rat model of HER2-expressing MTLn3 breast cancer in vivo. Summary of adverse events observed with intravenous administration of MTLn3 tumor bearing rats with either PBS (control), rat IgEs 20, 23 or 26, shown for each treatment condition and across different doses. Bottom right graph: animal weight measurements for each treatment group over time until termination.